<DOC>
	<DOCNO>NCT00187083</DOCNO>
	<brief_summary>The main purpose study find form asparaginase ( native E. coli/Erwinia ) PEG-asparaginase ) effective induction treatment child acute lymphoblastic leukemia come back treatment ( relapse ) resistant treatment ( refractory )</brief_summary>
	<brief_title>A Study Children With Refractory Relapsed ALL</brief_title>
	<detailed_description>The present protocol compare biologic effect PEG-asparaginase v native-forms asparaginase randomize trial use dosage schedule use POG 9411 study . Comprehensive study , include measurement antibody asparagine level well pharmacokinetics L-asparaginase , perform . This protocol also study change topoisomerase I topoisomerase II level fraction topoisomerase I/II translocation malignant lymphoblast upfront window topotecan therapy , correlate oncolytic response change . Secondary objective include : - To compare change asparagine level 28 day initiation treatment asparaginase two group . - To estimate pharmacokinetics L-asparaginase , compare pharmacokinetics two group patient , correlate pharmacokinetics development antibody asparaginase depletion asparagine . - To measure pharmacokinetics pharmacodynamics topotecan patient recurrent acute lymphoblastic leukemia - To determine whether frequency recombinogenesis lymphocyte increase etoposide therapy relative pre-therapy level , explore whether etoposide pharmacokinetics related Day 7 post-therapy level recombinogenesis . Detailed Description Treatment Plan WINDOW Topotecan 2.4 mg/m2 ; IV 30 min 5 dos Days 1-5 STANDARD INDUCTION Dexamethasone 6 mg/m2/day orally Days 8-35 Vincristine 1.5 mg/m2 ( max 2.0 mg ) day 8 , 15 , 22 , 29 RANDOMIZE E. coli asparaginase 10,000 U/m2/day IM ( Erwinia previous allergy E. coli ) Days 8 , 11 , 13 , 15 , 18 , 20 , 22 , 25 , 27 , 29 , 32 , 34 OR PEG-Asparaginase 2500 U/m2/day IM Days 8 , 15 , 22 , 29 ITHMA Days 8 , 22 , 36 CONSOLIDATION Fludarabine : 15 mg/m2 IV 30 min ; day 1,2,3,4 Ara-C : 2 g/m2 IV day 1,2,3,4 Patients achieve remission R16 induction consolidation may eligible either match sibling fully matched/one-antigen-mismatched unrelated donor transplant For patient undergo bone marrow transplant : SECONDARY CONSOLIDATION VP 16 : 50 mg/m2 PO qd 14 day . Vincristine : 1.5 mg/m2 ( max 2.0 mg ) IV ; day 1 , 8 . IT MHA day 1 CONTINUATION CHEMOTHERAPY Cycle 1 : Cyclophosphamide 1 g/m2 IV day 1 2 Vincristine 1.5 mg/m2 IV day 1 ( max 2.0 mg ) Cycle 2 : VP-16 50 mg/m2 day PO daily x 14 day Decadron 6 mg/m2 PO daily ) TID x 14 day Vincristine 1.5 mg/m2 IV ( max 2 mg ) day 1 8 . Cycle 3 : HD MTX 5 gm/m2 continuous infusion 24 hr E. coli Asparaginase 10,000 U/m2/dose IM qod x3 PEG Asparaginase 2500 U/m2/dose IM x 1 ( maintain randomization Asparaginase preparation induction ) Cycle 4 : High Dose Ara-C 2 g/m2/dose IV 2 hr q 12 hr x 3 dos . [ Total dose 6 gm/m2 ] Idarubicin 12 mg/m2 IV 30 min X 1 [ completion first dose Ara-C ] IT MHA day 1 prior HDARA-C ( dose ITMHA age adjust outlined section 7.3 ) STANDARD CONTINUATION CHEMOTHERAPY Patients receive 4-week rotational cycle chemotherapy follow pair drug total treatment duration 17 month . Week # 1 Cyclophosphamide ( 300 mg/m2 IV ) + VCR ( 1.5 mg/m2 IV ; max 2 mg ) . Week # 2 VM26 ( 200 mg/m2 IV ) + Ara C ( 300 mg/m2 IV ) . Week # 3 MTX ( MTX give IM 2 hr IV infusion patient previous cranial iradiation ) ( 40 mg/m2 IV/IM ) + 6 MP ( 75 mg/m2 PO q HS x 7 ) Week # 4 MTX ( MTX give IM 2 hr IV infusion patient previous cranial irradiation ) ( 40 mg/m2 IV/IM ) + 6 MP ( 75 mg/m2 PO q HS x 7 ) IT MHA : Given every 8 week throughout standard continuation chemotherapy patient CNS 1 status Given every 4 week patient CNS 2/3 status receive CSI end chemotherapy</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Teniposide</mesh_term>
	<criteria>Inclusion Criteria For patient treated frontline protocol St. Jude : ALL isolate bone marrow relapse , combine marrow extramedullary relapse , treatment multiagent chemotherapy ( TOTAL XI , XII , XIIIA , XIIIB ) , isolated extramedullary relapse treatment TOTXII . Patients recurrent TCell nonHodgkin 's lymphoma relapse bone marrow &gt; 25 % blast For patient treated frontline St. Jude protocol : â€¢ ALL isolated bone marrow relapse , isolate extramedullary relapse , combine marrow extramedullary relapse . All patient : First relapse receive primary therapy primary therapy Life expectance least 8 week ECOG score 02 Exclusion criterion Life expectancy &lt; 8 week</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Refractory Acute Lymphoblastic Leukemia</keyword>
	<keyword>Relapsed Acute Lymphoblastic Leukemia</keyword>
</DOC>